Answers are grounded in this paper and cite their sources.
In this trial involving patients with familial adenomatous polyposis, the incidence of disease progression was not significantly lower with the combination of eflornithine and sulindac than with either drug alone. (Funded by Cancer Prevention Pharmaceuticals; ClinicalTrials.gov number, NCT01483144; EudraCT number, 2012-000427-41.).
No takes yet. Share an insight, caveat, or question.
Burke et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: